ERYP.PA
ERYTECH Pharma S.A. [ERYP.PA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ERYP.PA Stock Summary
In the News
ERYP.PA Financial details
Company Rating
-
Market Cap
48.66M
Income
614K
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
49
Optionable
No
Shortable
Yes
Earnings
11 Sep 2023
P/E
40.46
Forward P/E
-
PEG
-4.03
P/S
-
P/B
1.06
P/C
-
P/FCF
-
Quick Ratio
3.54
Current Ratio
3.65
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.01
EPS next Y
-
EPS next Q
-
EPS this Y
-99.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-211.76%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
1%
ROE
3%
ROC
-0.08%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.285-1.479
52W High
-
52W Low
-
RSI
-
Rel Volume
0.13
Avg Volume
215.2K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
2.12912
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 215.2K
- Market Capitalization 48.66M
- Employee 49
- CEO Mr. Gil Beyen M.B.A.
- Headquarters Lyon,FR
- IPO Date 2013-05-07
-
Website
https://www.erytech.com 
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
